Siyuan Le

3.7k total citations · 1 hit paper
12 papers, 3.1k citations indexed

About

Siyuan Le is a scholar working on Molecular Biology, Oncology and Physiology. According to data from OpenAlex, Siyuan Le has authored 12 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Physiology. Recurrent topics in Siyuan Le's work include Cancer-related Molecular Pathways (4 papers), Telomeres, Telomerase, and Senescence (4 papers) and RNA Interference and Gene Delivery (3 papers). Siyuan Le is often cited by papers focused on Cancer-related Molecular Pathways (4 papers), Telomeres, Telomerase, and Senescence (4 papers) and RNA Interference and Gene Delivery (3 papers). Siyuan Le collaborates with scholars based in United States and China. Siyuan Le's co-authors include Carol W. Greider, Scott L. Weinrich, Richard Allsopp, Choy‐Pik Chiu, Ariel A. Avilion, Edwin Chang, Calvin B. Harley, William H. Andrews, Robert R. Adams and Junli Feng and has published in prestigious journals such as Science, Journal of Biological Chemistry and Neuron.

In The Last Decade

Siyuan Le

10 papers receiving 3.1k citations

Hit Papers

The RNA Component of Human Telomerase 1995 2026 2005 2015 1995 500 1000 1.5k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Siyuan Le United States 8 2.3k 1.9k 308 268 256 12 3.1k
Sahn-Ho Kim United States 16 1.6k 0.7× 1.5k 0.8× 98 0.3× 136 0.5× 335 1.3× 19 2.4k
Laurey Comeau United States 15 2.5k 1.1× 1.5k 0.8× 130 0.4× 136 0.5× 273 1.1× 16 3.3k
Alessandro Bianchi Switzerland 25 3.7k 1.6× 3.4k 1.8× 217 0.7× 237 0.9× 778 3.0× 37 4.8k
Yie Liu United States 31 1.8k 0.8× 919 0.5× 66 0.2× 201 0.8× 189 0.7× 62 2.5k
Patrick Reichenbach Switzerland 22 2.4k 1.0× 1.4k 0.7× 77 0.3× 200 0.7× 209 0.8× 38 3.3k
Diego Loayza United States 14 1.5k 0.7× 1.3k 0.7× 99 0.3× 120 0.4× 228 0.9× 17 1.9k
Sohee Jun United States 21 1.4k 0.6× 592 0.3× 137 0.4× 152 0.6× 106 0.4× 28 2.0k
Isabel López de Silanes Spain 30 2.9k 1.3× 478 0.3× 74 0.2× 202 0.8× 84 0.3× 36 3.7k

Countries citing papers authored by Siyuan Le

Since Specialization
Citations

This map shows the geographic impact of Siyuan Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Siyuan Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Siyuan Le more than expected).

Fields of papers citing papers by Siyuan Le

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Siyuan Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Siyuan Le. The network helps show where Siyuan Le may publish in the future.

Co-authorship network of co-authors of Siyuan Le

This figure shows the co-authorship network connecting the top 25 collaborators of Siyuan Le. A scholar is included among the top collaborators of Siyuan Le based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Siyuan Le. Siyuan Le is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Jiang, Tao, Siyuan Le, Leitao Zhang, et al.. (2025). Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors. Journal of Medicinal Chemistry. 68(15). 15386–15402.
2.
Pachter, Jonathan A., Feng Yan, Sílvia Coma, et al.. (2025). Abstract 4394: GFH375 (VS-7375): An oral, selective KRAS G12D (ON/OFF) inhibitor with potent anti-tumor efficacy as single agent and in combination with other anticancer therapies in preclinical models. Cancer Research. 85(8_Supplement_1). 4394–4394. 2 indexed citations
4.
Zhou, Fusheng, et al.. (2022). In Vitro and In Vivo Studies Support GFH009, a Selective CDK9 Inhibitor, As a Potential Treatment for Hematologic Cancers. Blood. 140(Supplement 1). 7808–7809. 2 indexed citations
5.
Putcha, Girish, Siyuan Le, Stephan Frank, et al.. (2003). JNK-Mediated BIM Phosphorylation Potentiates BAX-Dependent Apoptosis. Neuron. 38(6). 899–914. 436 indexed citations
6.
Le, Siyuan, Thomas J. Connors, & Anna C. Maroney. (2001). c-Jun N-terminal Kinase Specifically Phosphorylates p66ShcA at Serine 36 in Response to Ultraviolet Irradiation. Journal of Biological Chemistry. 276(51). 48332–48336. 88 indexed citations
7.
Le, Siyuan, Rolf Sternglanz, & Carol W. Greider. (2000). Identification of Two RNA-binding Proteins Associated with Human Telomerase RNA. Molecular Biology of the Cell. 11(3). 999–1010. 106 indexed citations
8.
Le, Siyuan, J. Kent Moore, James E. Haber, & Carol W. Greider. (1999). RAD50 and RAD51 Define Two Pathways That Collaborate to Maintain Telomeres in the Absence of Telomerase. Genetics. 152(1). 143–152. 332 indexed citations
9.
Le, Siyuan, Jay Zhu, Douglas C. Anthony, Carol W. Greider, & Peter McL. Black. (1998). Telomerase Activity in Human Gliomas. Neurosurgery. 42(5). 1120–1124. 58 indexed citations
10.
Le, Siyuan, Colleen Davis, James B. Konopka, & Rolf Sternglanz. (1997). Two New S-Phase-Specific Genes fromSaccharomyces cerevisiae. Yeast. 13(11). 1029–1042. 188 indexed citations
11.
Feng, Junli, Walter D. Funk, Scott L. Weinrich, et al.. (1995). The RNA Component of Human Telomerase. Science. 269(5228). 1236–1241. 1871 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026